Tycel Phillips, MD
Hematology · Duarte, CANPI 1568607653
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $259,190 of the $347,633 with a category attached, or 74.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 14.4%. Reporting peaked in 2023 at $120,600 and has fallen 56.8% since, to $52,132 in 2025. Among hematology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $1047.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$50K
- ADC Therapeutics America, Inc.$37K
- Genmab U.S., Inc.$36K
- Genentech, Inc.$33K
- AstraZeneca$30K
- Genentech USA, Inc.$26K
- plus $135K from 23 others
Across 1,003 payments — averaging $21,176 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$9.5M
- Beigene, Ltd.$4.4M
- Genentech, Inc.$3.2M
- Acerta Pharma LLC$829K
- Incyte Corporation$636K
- Bayer$592K
- plus $2.1M from 23 others
What the payments were for
- Consulting fees$259,19075%
- Speaking & faculty fees$50,63915%
- Travel & lodging$28,4968%
- Food & beverage$9,3083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 71 | $49,942 |
| ADC Therapeutics America, Inc. | 52 | $37,082 |
| Genmab U.S., Inc. | 23 | $36,393 |
| Genentech, Inc. | 13 | $32,719 |
| AstraZeneca | 20 | $30,169 |
| Genentech USA, Inc. | 31 | $26,198 |
| Gilead | 23 | $26,193 |
| E.r. Squibb & Sons, L.L.C. | 8 | $19,719 |
| Incyte Corporation | 6 | $16,730 |
| Beigene USA, Inc. | 9 | $8,546 |
| Eli Lilly | 6 | $8,230 |
| Pfizer | 5 | $7,853 |
| Merck | 9 | $7,800 |
| Pharmacyclics LLC, An Abbvie Company | 13 | $6,827 |
| Beone Medicines USA, Inc. | 3 | $5,780 |
| Roche Products Limited | 4 | $5,750 |
| Seagen Inc. | 7 | $5,671 |
| Astrazeneca UK Limited | 3 | $4,574 |
| Ipsen Biopharmaceuticals, Inc | 3 | $3,724 |
| Bristol Myers Squibb | 11 | $3,465 |
| Janssen Global Services, LLC | 1 | $1,410 |
| Bayer | 1 | $900 |
| Epizyme, Inc. | 1 | $725 |
| Johnson & Johnson | 1 | $720 |
| Novartis | 3 | $158 |
| CTI Biopharma Corp. | 1 | $155 |
| Taiho Oncology, Inc. | 2 | $105 |
| F. Hoffmann-la Roche AG | 1 | $69 |
| Pharmaessentia USA Corporation | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$347,633 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 38 | $574,078 |
| RevlimidLenalidomide | 29 | $364,705 |
| Acyclovir | 28 | $394 |
| Dexamethasone | 16 | $200 |
| Prednisone | 21 | $69 |
| Allopurinol | 13 | $67 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $8,546 | $574,07838 claims |
| Bristol Myers SquibbRevlimid | $3,465 | $364,70529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 178 hematology providers in California.
Other hematology in Duarte
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Alexey DanilovDuarte$407K
- Haris AliDuarte$310K
- Amandeep SalhotraDuarte$214K
- Tanya SiddiqiDuarte$199K
- Scott GoldsmithDuarte$180K
- Ibrahim AldossDuarte$175K
- Alex HerreraDuarte$155K
- Geoffrey ShouseDuarte$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.